Navigation Links
Researchers challenge previous findings regarding widely used asthma treatment
Date:1/10/2008

WINSTON-SALEM, N.C. A new study published recently in The Lancet reveals that one of the most commonly used asthma medicines -- long-acting beta-agonists -- may not be associated with adverse events in people based on their genotype (gene variation), as previous studies had shown.

The study analyzed the effects of long-acting beta-agonist therapy, used in combination with inhaled corticosteroids, in asthmatics who have a specific beta-2 adrenergic receptor (ADRB2) genotype.

Investigators analyzed data from two clinical trials performed by AstraZeneca Pharmaceuticals LP. In each trial, patients were randomized to receive one of two different long-acting beta-agonists. In the case of each of the therapies, asthma symptoms and control improved, but no differences were observed based on the ADRB2 genotype.

These results are extremely important because previous studies on short-acting beta-agonists showed evidence for an adverse genotypic effect, said Eugene R. Bleecker, M.D., Thomas H. Davis Professor of Medicine, co-director of Center for Human Genomics at Wake Forest Baptist, and lead-investigator for the study. Smaller studies on long-acting beta-agonists have produced conflicting results.

Current guidelines recommend the use of combination therapy, with long-acting beta-agonists and inhaled corticosteroids, to control moderate to severe persistent asthma.

With over 2,000 patients in this study receiving combination therapy, it was reassuring that no adverse safety effects could be attributed to an individuals genotype, said Bleecker.

Ten percent of the U.S. population suffers from asthma. Each year, approximately 4,000 people die with asthma as the underlying cause.


'/>"/>

Contact: Shannon Koontz
shkoontz@wfubmc.edu
336-716-2415
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. UT Health Science Center researchers decoding saliva to detect breast cancer
2. Protein power: Researchers trigger insulin production in diabetic mice
3. Researchers use neuroimaging to study ESP
4. UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
5. Researchers seek to make cavity-causing bacteria self-destruct
6. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
7. New research tools are too complex for easy answers, researchers say
8. In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
9. U of M researchers discover fast-acting cyanide antidote
10. SLU researchers show how to stop muscle weakness caused by myasthenia gravis
11. Researchers solve first structure of a key to intact DNA inheritance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology: